Literature DB >> 15247773

Optical characteristics of the canine prostate at 665 nm sensitized with tin etiopurpurin dichloride: need for real-time monitoring of photodynamic therapy.

Jerzy Jankun1, Lothar Lilge, Alexander Douplik, Rick W Keck, Maciej Pestka, Maria Szkudlarek, Phillip J Stevens, Robert J Lee, Steven H Selman.   

Abstract

PURPOSE: Photodynamic therapy (PDT) is an emerging, minimally invasive therapy for prostate cancer that depends on the sequestration of a photosensitizing drug within targeted tissue. The photosensitizer is subsequently activated by light of a specific wavelength, resulting in destruction of the targeted tissue. Successful treatment requires knowledge of the optical properties of the target tissue, a critical element for therapy.
MATERIALS AND METHODS: Adult canines were injected with tin etiopurpurin dichloride (1.0 mg/kg) as a liposome emulsion vehicle in saline 24 hours prior to light treatment. Laser light was delivered to the prostate via a 400 microm optical fiber fitted with a 2.0 cm cylindrical diffuser and optical properties of the prostate were measured.
RESULTS: In this study we determined the attenuation coefficient and critical fluence in the canine prostate. Our studies shown that the attenuation coefficient is not uniform but higher at the base (average for all animals 2.59 to 2.79 cm-1) than in the mid section or apex of the prostate (1.71 to 1.90 cm-1). Significant differences among dogs (0.11 to 12.70 cm-1) were found. In some cases we observed a fluctuation of the attenuation coefficient during treatment. We also established experimentally the minimum energy (1449 mJ/cm2) needed (critical fluence) to produce necrosis. Experimentally establishing the values of effective attenuation and critical fluence is necessary to predict the area of ablation during PDT and protect surrounding organs from over treatment.
CONCLUSIONS: Based on our results it is evident that for PDT of the prostate to be successful the optical parameters of the prostate must be measured and monitored during treatment. We suggest that the optimum way of doing this is real-time computerized monitoring combined with simulation PDT.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15247773     DOI: 10.1097/01.ju.0000135304.96496.20

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  4 in total

Review 1.  A review of progress in clinical photodynamic therapy.

Authors:  Z Huang
Journal:  Technol Cancer Res Treat       Date:  2005-06

2.  Treatment planning using tailored and standard cylindrical light diffusers for photodynamic therapy of the prostate.

Authors:  Augusto Rendon; J Christopher Beck; Lothar Lilge
Journal:  Phys Med Biol       Date:  2008-02-05       Impact factor: 3.609

3.  Studies of a vascular-acting photosensitizer, Pd-bacteriopheophorbide (Tookad), in normal canine prostate and spontaneous canine prostate cancer.

Authors:  Zheng Huang; Qun Chen; David Luck; Jill Beckers; Brian C Wilson; Nadira Trncic; Susan M Larue; Dominique Blanc; Fred W Hetzel
Journal:  Lasers Surg Med       Date:  2005-06       Impact factor: 4.025

Review 4.  Photodynamic therapy for treatment of solid tumors--potential and technical challenges.

Authors:  Zheng Huang; Heping Xu; Arlen D Meyers; Ali I Musani; Luowei Wang; Randall Tagg; Al B Barqawi; Yang K Chen
Journal:  Technol Cancer Res Treat       Date:  2008-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.